Qiming Venture Partners Portfolio Stars: Five Female Leaders Make Fortune China’s Most Powerful Women Future List
China's Most Influential Businesswomen (Future List) spotlights trendsetting female leaders with unlimited potential.
Recently, Fortune China released its 2025 Most Powerful Women in Business list, which includes both the main Most Powerful Women ranking and the Most Powerful Women: Future list, reflecting the year's most important and cutting-edge business trends. The Future list spotlights women leaders who are setting trends and possess unlimited potential.
Five Qiming Venture Partners portfolio companies are represented on the 2025 Fortune China Most Powerful Women: Future list: Shi Haoying, founder and CEO of YourHealth Medical; Qiu Xiaoxin, founder, chairwoman, and CEO of Axera; Li Xuan, CFO and head of international at WeRide (NASDAQ: WRD); Sun Shuli, co-founder and chief product officer at Yuanbao Inc. (NASDAQ: YB); and Zheng Rujing, founder and CEO of Spēs.
Shi Haoying, Founder and CEO, YourHealth Medical
Qiu Xiaoxin, Founder, Chairwoman, and CEO, Axera
Li Xuan, CFO and Head of International, WeRide
Sun Shuli, Co-founder and Chief Product Officer, Yuanbao Inc.
Zheng Rujing, Founder and CEO, Spēs
Named to the
2025 Fortune China Most Powerful Women: Future List
The Fortune China Most Powerful Women list was launched in 2010 to showcase the wisdom, courage, perseverance, and confidence of women leaders in Chinese business. This year's theme is "Finding Real Incremental Growth." The efforts and achievements of the listed women have not only written a new template for leadership but also offered answers to an important and urgent question: in this era of uncertainty, how can we achieve sustainable, high-quality growth through continuous innovation and by finding new growth points and value spaces?
Fortune China noted that more entrepreneurs working in AI have made the list this year. **Generative AI technology is gaining strong momentum, large model iterations continue to accelerate, and the vast China market provides rich and diverse application scenarios for AI technology deployment. Building on these advantages, the listed women are focusing on areas including intelligent driving chip R&D, enterprise intelligent decision-making, biopharmaceutical R&D, cancer cell identification and diagnosis, intelligent solid waste sorting, and smart charging for new energy vehicles. These women leaders generally possess deep academic and technical foundations alongside outstanding management and operational capabilities. They are not only using AI technology to drive innovation and transformation across multiple industries but also working to promote the inclusive application of technology.
Source | Fortune China
Past Coverage
Qiming Stars | Multiple Qiming Venture Partners Portfolio Companies Appear at 2025 Summer Davos
Qiming Weekly | Qiming Venture Partners Portfolio Company Funding and Updates Vol. 24, 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the technology and healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.